Navigation Links
Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Date:10/1/2013

NEW YORK, Oct. 1, 2013 /PRNewswire/ -- Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the final closing of a Series A financing raising $8 million in gross proceeds.  The offer was oversubscribed and Laidlaw & Company (UK) Ltd. acted as the exclusive placement agent.   

The company intends to use the Series A proceeds to continue the development of its product pipeline and for general corporate activities.  "This impressive response from investors clearly shows the potential of our diversified product portfolio of drug candidates aimed to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada.  Based on this successful offering, we plan to complete the required steps for LevoCap ER to enter Phase III of development, d-methadone to enter Phase IIb, MepiGel and BuCap to start the pilot PK studies and to prepare the company for a public transaction in the first half of 2014.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain.  Relmada's strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform. 

The Company is currently developing several drug candidates including: LevoCap ER, its abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN); BuCap, its oral dosage form of the opioid analgesic buprenorphine; MepiGel, its FDA Orphan Drug designated topica
'/>"/>

SOURCE Relmada Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ... low. The only negative is the housing market remaining ...
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... WOODLANDS, Texas, Oct. 4 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... Lexicon,s president and chief executive officer, will present,at the ... California,on Thursday, October 11, 2007 at 11:00 a.m. Pacific ... be accessed on its,corporate website at http://www.lexpharma.com . ...
... In conjunction with,its third quarter 2007 earnings release (expected ... (NYSE: CVD ) is pleased to invite you to,listen ... over the Internet on Thursday, October 25 at 9:00 a.m. ... Webcast and Slide Presentation When: October 25, ...
... VRUS ) has entered into a working capital loan ... and conditions of,the agreement, Horizon will advance $10 million ... may receive a second loan of $10 million,by March ... by November 30, 2008,provided conditions precedent to making the ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... If grandma seems to forget things, will she end up ... few symptoms that may signal which 70-year-olds risk developing dementia. ... Academy at the University of Gothenburg, Sweden. Several of ... developing dementia do not seem to work any longer. The ...
... in Spanish . , DNA-Prokids ( http://www.dna-prokids.org ... using genetic identification of victims and their relatives, was officially ... (UGR) headquarters, in Spain. Traffic in human beings is ... beginning of the 21st century. According to data from the ...
... Iowa -- Researchers at Iowa State University have discovered ... plant growth. , Yanhai Yin, an assistant professor in ... a plant hormone called brassinosteroids. The hormone controls the ... major impact on how large the plant grows, says ...
Cached Biology News:Early identification of dementia increasingly difficult 2DNA-Prokids: Genetic identification against traffic in human beings 2ISU researcher identifies genetic pathway responsible for much of plant growth 2
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
...
Biology Products: